Ridruejo Ezequiel, Pereson Matías Javier, Flichman Diego M, Di Lello Federico Alejandro
Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC", Ciudad Autónoma de Buenos Aires C1425AS, Unspecified, Argentina.
Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina.
World J Hepatol. 2021 Sep 27;13(9):1069-1078. doi: 10.4254/wjh.v13.i9.1069.
The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.
丙型肝炎病毒具有很高的突变能力，可导致耐药相关替代（RAS）的出现。然而，在新型直接抗病毒药物（DAA）治疗期间进行耐药选择的后果不一定是治疗失败。事实上，即使报告了较高的基线RAS流行率，DAA治疗仍显示出较高的持续病毒学应答率（>95%）。在RAS出现和高持续病毒应答率的背景下，携带RAS的变异体的临床相关性仍存在争议。因此，为了总结国际指南中的现有数据，我们回顾了在新型泛基因型DAA药物时代检测RAS的临床实用性。
